Latest news with #RCC
Time of India
a day ago
- Business
- Time of India
Greater Hyderabad Municipal Corporation to renew 100 RCC toilets across Secunderabad
HYDERABAD: The Greater Hyderabad Municipal Corporation ( GHMC ) decided to reuse, refurbish, and utilise over 100 existing RCC toilets, e-toilets, and bio-toilets in the Secunderabad zone. The civic body invited 'expressions of interest' from safai karamchari registered bodies under the Build Operate and Transfer (BOT) model to adopt a pay-and-use system for 10 years. The agency needs to reconstruct toilets with amenities, including structural, plumbing, electrical, and lighting works. It should provide essential services such as liquid soap, napkins, dustbins, mirrors, and exhaust fans for users. You Can Also Check: Hyderabad AQI | Weather in Hyderabad | Bank Holidays in Hyderabad | Public Holidays in Hyderabad
Yahoo
2 days ago
- Business
- Yahoo
Here's Why This $50 Healthcare Stock Could Be the Next $200 Winner
Key Points Exelixis' most important product should continue driving strong financial results through the end of the decade. The oncology specialist is working on a next-gen medicine that could be even better than its crown jewel. The midcap biotech looks well-positioned to deliver market-beating returns over the long run. 10 stocks we like better than Exelixis › A decade ago, shares of Exelixis (NASDAQ: EXEL), a biotech company specializing in oncology, were trading for under $10 per share. Today, the drugmaker's shares are changing hands for about $45 apiece. In other words, Exelixis has crushed the market since 2015. Some might think there is little upside left for the stock after this run, but that's not the case. Read on to find out why Exelixis still has plenty of growth fuel left in the tank. Cabometyx is still doing the heavy lifting Exelixis is best known for its cancer medicine, Cabometyx. First approved in the U.S. in 2016 for patients with renal cell carcinoma (RCC, a form of kidney cancer), it was a bit of a breakthrough as the first therapy to show significant improvements for RCC patients in three important measures: overall survival, progression-free survival, and objective response rate (the percentage of patients who respond to treatment). Cabometyx has since earned numerous label expansions, and it continues to help drive solid top- and bottom-line growth for Exelixis. In the first quarter, the company's revenue jumped by 30.6% year over year to $555.4 million. The company's adjusted earnings per share (EPS) more than tripled to $0.62. Cabometyx has proven to be a successful pipeline drug, becoming the most prescribed tyrosine kinase inhibitor (a type of cancer drug that targets and kills cancer cells) among RCC patients, while making headway in hepatocellular carcinoma (liver cancer) and other markets. Despite Cabometyx's success, though, Exelixis will need more to continue delivering above-average returns over the long run. Generic competition for the medicine is expected to enter the U.S. market by 2030. Thankfully, Exelixis is already preparing for that eventuality. The next stage of growth Exelixis aims to apply the same blueprint that has made it successful over the past decade: developing a cancer medicine that can become a standard of care in a niche with a high unmet need, while earning label expansions in many other markets. The company appears to have already discovered its next gem. Exelixis recently reported positive top-line phase 3 results for zanzalintinib in patients with metastatic colorectal cancer (CRC). Despite having a high 5-year survival rate when caught early, CRC is the second-leading cause of cancer death worldwide partly because, once it has metastasized, there are few effective treatment options. Exelixis is looking to change that with zanzalintinib, and the company's apparent phase 3 success suggests it might be able to pull it off. Furthermore, zanzalintinib is being investigated across other indications, including those where Cabometyx is dominant, such as RCC. The former seems to have a better safety profile than its predecessor, among several other advantages. Beyond RCC and CRC, Exelixis plans to start several other late-stage studies for its next crown jewel this year, all of which will test it against current standards of care. As they say, to be the best, you have to beat the best. That's what Exelixis aims to do with zanzalintinib. Exelixis expects zanzalintinib to generate about $5 billion in sales eventually, far exceeding Cabometyx's current total or, for that matter, Exelixis' annual revenue. There is still some work to be done to get there, but early signs suggest that zanzalintinib is an excellent candidate. Exelixis' recent clinical progress also reinforces its leadership in oncology. The biotech company has several other early-stage candidates in development that could help it move beyond Cabometyx once it starts facing generic competition. Can Exelixis get to $200? From its current stock price of approximately $45, Exelixis needs a compound annual growth rate (CAGR) of at least 16.1% to reach $200 within the next decade and 10.5% to achieve this in 15 years. The former goal is ambitious, but the stock has delivered even better returns than that over the past decade. Although the past is no guarantee of future success, Exelixis' MO has remained the same and could, once again, allow it to generate monster returns over the long run as it makes significant clinical and regulatory progress with zanzalintinib and other pipeline candidates. Even if it falls short of this goal, though, my view is that Exelixis is well-positioned to deliver market-beating returns to patient investors -- the 15-year path to $200 would still be impressive. Either way, the stock looks like a buy. Should you invest $1,000 in Exelixis right now? Before you buy stock in Exelixis, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Exelixis wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $652,133!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,056,790!* Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 15, 2025 Prosper Junior Bakiny has positions in Exelixis. The Motley Fool has positions in and recommends Exelixis. The Motley Fool has a disclosure policy. Here's Why This $50 Healthcare Stock Could Be the Next $200 Winner was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
2 days ago
- Business
- Globe and Mail
Here's Why This $50 Healthcare Stock Could Be the Next $200 Winner
Key Points Exelixis' most important product should continue driving strong financial results through the end of the decade. The oncology specialist is working on a next-gen medicine that could be even better than its crown jewel. The midcap biotech looks well-positioned to deliver market-beating returns over the long run. 10 stocks we like better than Exelixis › A decade ago, shares of Exelixis (NASDAQ: EXEL), a biotech company specializing in oncology, were trading for under $10 per share. Today, the drugmaker's shares are changing hands for about $45 apiece. In other words, Exelixis has crushed the market since 2015. Some might think there is little upside left for the stock after this run, but that's not the case. Read on to find out why Exelixis still has plenty of growth fuel left in the tank. EXEL Total Return Level data by YCharts. Cabometyx is still doing the heavy lifting Exelixis is best known for its cancer medicine, Cabometyx. First approved in the U.S. in 2016 for patients with renal cell carcinoma (RCC, a form of kidney cancer), it was a bit of a breakthrough as the first therapy to show significant improvements for RCC patients in three important measures: overall survival, progression-free survival, and objective response rate (the percentage of patients who respond to treatment). Cabometyx has since earned numerous label expansions, and it continues to help drive solid top- and bottom-line growth for Exelixis. In the first quarter, the company's revenue jumped by 30.6% year over year to $555.4 million. The company's adjusted earnings per share (EPS) more than tripled to $0.62. Cabometyx has proven to be a successful pipeline drug, becoming the most prescribed tyrosine kinase inhibitor (a type of cancer drug that targets and kills cancer cells) among RCC patients, while making headway in hepatocellular carcinoma (liver cancer) and other markets. Despite Cabometyx's success, though, Exelixis will need more to continue delivering above-average returns over the long run. Generic competition for the medicine is expected to enter the U.S. market by 2030. Thankfully, Exelixis is already preparing for that eventuality. The next stage of growth Exelixis aims to apply the same blueprint that has made it successful over the past decade: developing a cancer medicine that can become a standard of care in a niche with a high unmet need, while earning label expansions in many other markets. The company appears to have already discovered its next gem. Exelixis recently reported positive top-line phase 3 results for zanzalintinib in patients with metastatic colorectal cancer (CRC). Despite having a high 5-year survival rate when caught early, CRC is the second-leading cause of cancer death worldwide partly because, once it has metastasized, there are few effective treatment options. Exelixis is looking to change that with zanzalintinib, and the company's apparent phase 3 success suggests it might be able to pull it off. Furthermore, zanzalintinib is being investigated across other indications, including those where Cabometyx is dominant, such as RCC. The former seems to have a better safety profile than its predecessor, among several other advantages. Beyond RCC and CRC, Exelixis plans to start several other late-stage studies for its next crown jewel this year, all of which will test it against current standards of care. As they say, to be the best, you have to beat the best. That's what Exelixis aims to do with zanzalintinib. Exelixis expects zanzalintinib to generate about $5 billion in sales eventually, far exceeding Cabometyx's current total or, for that matter, Exelixis' annual revenue. There is still some work to be done to get there, but early signs suggest that zanzalintinib is an excellent candidate. Exelixis' recent clinical progress also reinforces its leadership in oncology. The biotech company has several other early-stage candidates in development that could help it move beyond Cabometyx once it starts facing generic competition. Can Exelixis get to $200? From its current stock price of approximately $45, Exelixis needs a compound annual growth rate (CAGR) of at least 16.1% to reach $200 within the next decade and 10.5% to achieve this in 15 years. The former goal is ambitious, but the stock has delivered even better returns than that over the past decade. Although the past is no guarantee of future success, Exelixis' MO has remained the same and could, once again, allow it to generate monster returns over the long run as it makes significant clinical and regulatory progress with zanzalintinib and other pipeline candidates. Even if it falls short of this goal, though, my view is that Exelixis is well-positioned to deliver market-beating returns to patient investors -- the 15-year path to $200 would still be impressive. Either way, the stock looks like a buy. Should you invest $1,000 in Exelixis right now? Before you buy stock in Exelixis, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Exelixis wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $652,133!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,056,790!* Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 15, 2025
Observer
2 days ago
- Business
- Observer
Raysut Cement reports strong H1, global gains
MUSCAT, JULY 19 Raysut Cement Company (RCC) Group, Oman's largest cement producer, has reported a significant financial turnaround in the first half of 2025, marking a major step in its transformation into a resilient and forward-looking industry leader. The Group's consolidated revenue rose by 30.8% to RO 41.3 million, while net losses were reduced by 38% compared to the same period in 2024. This performance reflects a successful strategy implemented across its operations, including key contributions from its UAE-based subsidiary Pioneer Cement Industries and its growing presence in the Maldives. Pioneer Cement Industries (PCI), a wholly owned subsidiary of RCC in the UAE, has become a central pillar in the Group's recovery. PCI's capacity utilisation surged to 88% in the first half of the year, up from just 40% during the same period in 2024. This turnaround is attributed to improved operational discipline and a renewed commercial focus. PCI succeeded in attracting bulk cement customers in the UAE and increased its monthly sales by an average of 50,000 metric tonnes. It also developed premium clinker products with higher margins and introduced a smart pricing mechanism to enhance competitiveness. In an interview with the Observer, Acting CEO Dr Hilal Saif al Dhamri highlighted the importance of these strategic gains. 'Pioneer Cement's recovery is a textbook example of how operational excellence and smart market positioning can deliver real results,' he said. 'We have restored its reputation and repositioned it as a high-performing, quality-driven asset within our Group.' RCC's strategic expansion into the Maldives has also paid dividends. Its 75%-owned subsidiary, Maldives Raysut Cement Company, has become a preferred supplier for major infrastructure projects in the island nation. The Group now holds a 35% share of total cement imports to the Maldives. Despite logistical hurdles typical of island markets, the company introduced efficient distribution models and launched specialised marine-grade cement to meet coastal construction demands. Dr Hilal Saif al Dhamri, Acting CEO of Raysut Cement Company 'The Maldives is a key part of our international growth strategy,' Dr Al Dhamri added. 'We've established ourselves as a reliable partner for national development projects, and our localised approach is helping us build long-term customer trust.' On the sustainability front, RCC is setting new benchmarks at its flagship Salalah plant. The company is implementing a Waste Heat Recovery System that will generate 9MW of clean electricity annually, cutting CO₂ emissions by an estimated 50,000 tonnes per year and saving around RO 1.5 million in energy costs. Alongside this, a Refuse-Derived Fuel (RDF) project is being rolled out to process about 700 tonnes of municipal waste per day into alternative fuel, replacing 15% of the plant's natural gas consumption. These initiatives support Oman's environmental goals and demonstrate the financial viability of green technology in heavy industry. At the Sohar Cement Factory, monthly sales increased by 32,000 metric tonnes, contributing to stronger Group-wide performance. Strategic price optimisation in export markets has also helped bolster revenues and create a more sustainable business model. With these achievements, RCC is entering a new phase of sustained growth under Dr Al Dhamri's leadership. 'We've laid a strong foundation by revitalising our core operations, expanding internationally, and leading on sustainability,' he noted. 'Our focus now is to accelerate our momentum and secure our position as a regional industry leader.' As 2025 progresses, Raysut Cement stands as a model of industrial transformation—one that combines operational discipline, market diversification, and environmental responsibility to drive long-term value for Oman's cement sector and the wider region.
Medscape
5 days ago
- Health
- Medscape
Rapid Review Quiz: Advanced and Metastatic Renal Cell Carcinoma
Advanced and metastatic renal cell carcinoma (RCC) remains a complex and clinically significant disease that often presents diagnostic and therapeutic challenges. Whereas early-stage RCC can be curable with surgery, advanced RCC frequently carries a poor prognosis and demands nuanced, multidisciplinary management. Rapid advancements in systemic therapies, particularly immunotherapy and targeted agents, have transformed the treatment landscape, making ongoing clinical familiarity essential. Understanding current approaches to diagnosis, prognostication, and treatment selection is critical for optimizing outcomes in this evolving field. Patients with metastatic RCC have a 5-year survival rate of 17.4%. This contrasts greatly with the 5-year survival rate of 92.9% among patients with localized RCC. The overall 5-year survival rate in RCC is 78.6%, highlighting the dramatic impact of disease stage on long-term outcomes. Learn more about prognosis of RCC. The most common type of bone metastasis in RCC is osteolytic, resulting from bone resorption due to osteoclast activity. These lesions lead to bone destruction and are frequently associated with complications such as fractures. Osteoblastic lesions, characterized by excessive bone deposition, are associated with other types of cancer but are not commonly seen in RCC. Osteoblastic lesions are a type of sclerotic lesion. Learn more about imaging in RCC. A robust T-cell-mediated antitumor response requires activation of the local interferon gamma signaling pathway within the tumor microenvironment. Adaptive resistance to ICI therapy in RCC is largely attributed to an impaired response to interferon gamma, a key cytokine in anti-tumor immunity. The release of immunosuppressive cytokines can also contribute to resistance by dampening T-cell activity. However, resistance is not caused by a lack of immunosuppressive cells in the tumor microenvironment. On the contrary, regulatory T cells and myeloid-derived suppressor cells often accumulate in the tumor microenvironment and inhibit effective immune responses. Learn more about PD-1/PD-L1 inhibitors for RCC. CAR-T therapy has reshaped therapeutic approaches in several hematologic cancers, but its effectiveness in solid tumors such as RCC remains limited. This relatively reduced effectiveness is largely due to poor CAR T-cell infiltration into solid tumors and an immunosuppressive tumor microenvironment that impairs CAR-T activity. CAR-T therapies are still investigational in RCC, with no FDA-approved treatments currently available. Cytokine release syndrome (CRS) is one of the most common and clinically significant toxicities associated with CAR-T therapy. It is caused by elevated levels of inflammatory cytokines and may present with fever, myalgia, and arthralgia. In severe cases, CRS can lead to endothelial activation and disruption of the blood-brain barrier. Learn more about experimental therapeutic approaches for RCC. NCCN guidelines recommend initiating systemic therapy in patients with either extensive distant metastases or tumors containing a substantial sarcomatoid component before considering cytoreductive nephrectomy. Thermal ablation is typically reserved for select patients with stage T1 disease. Stereotactic body radiation therapy, another form of ablative therapy, may be appropriate for localized (stage I, II, or III) renal cancer in patients who are not ideal candidates for surgery. Current guidelines from the American Society of Clinical Oncology are aligned with these NCCN recommendations, stating that first-line treatment for patients with metastatic RCC exhibiting sarcomatoid features should be systemic therapy, specifically an ICI-based combination. This therapy may consist of ipilimumab plus nivolumab, or alternatively, an ICI paired with a tyrosine kinase inhibitor. Learn more about radiation therapy for RCC.
